Clinical course and management of children with IgA vasculitis with nephritis

• DOI: 10.1007/s00467-023-06023-8
• Publication Date: 2023-06-14T21:01:48Z
• Authors: Hillarey K. Stone; Mark Mitsnefes; Kimberley Dickinson; Evanette K. Burrows; Hanieh Razzaghi; Ingrid Y. Luna; Caroline A. Gluck; Bradley P. Dixon; Vikas R. Dharnidh...; William E. Smoyer; Michael J. Somers; Joseph T. Flynn; Susan L. Furth; Charles Bailey; Christopher B. Fo...; Michelle Denburg; Edward Nehus
• Keywords: Nephritis; IgA Vasculitis; ICTS (Institute of Clinical and Translational Sciences); Medicine and Health Sciences; Disease Progression; 610; Humans; Original Article; Renal Insufficiency; Chronic; Renal Insufficiency, Chronic; Child; Immunoglobulin A

Abstract Background IgA vasculitis is the most common vasculitis in children and is often complicated by acute nephritis (IgAVN). Risk of chronic kidney disease (CKD) among children with IgAVN remains unknown. This study aimed to describe the clinical management and kidney outcomes in a large cohort of children with IgAVN.

Methods This observational cohort study used the PEDSnet database to identify children diagnosed with IgAV between January 1, 2009, and February 29, 2020. Demographic and clinical characteristics were compared among children with and without kidney involvement. For children followed by nephrology, clinical course, and management patterns were described. Patients were divided into four categories based on treatment: observation, renin–angiotensin–aldosterone system (RAAS) blockade, corticosteroids, and other immunosuppression, and outcomes were compared among these groups.

Results A total of 6802 children had a diagnosis of IgAV, of whom 1139 (16.7%) were followed by nephrology for at least 2 visits over a median follow-up period of 1.7 years [0.4,4.2]. Conservative management was the most predominant practice pattern, consisting of observation in 57% and RAAS blockade in 6%. Steroid monotherapy was used in 29% and other immunosuppression regimens in 8%. Children receiving immunosuppression had higher rates of proteinuria and hypertension compared to those managed with observation (p < 0.001). At the end of follow-up, 2.6 and 0.5% developed CKD and kidney failure, respectively.

Conclusions Kidney outcomes over a limited follow-up period were favorable in a large cohort of children with IgAV. Immunosuppressive medications were used in those with more severe presentations and may have contributed to improved outcomes.

Graphical abstract